HeyJaredThe M&A Hunter
Tracking biotech acquisition targets before big pharma strikes. Featuring acquisition targets with detailed analysis M&A probability signals and catalysts Valuation insight and deal timing estimates Big pharma strategy patterns "NOT Pro Advice"
- Indexed issues, last 90 days
- 29
- Latest publication
- Oct 1, 2026
- Audience
- Checking…
- Earliest in this view
- Sep 15, 2026
Latest issues
Wednesday Deep Dive (opens the original)
Read excerpt
Monte Rosa Therapeutics (GLUE): The Day Before the DataThis Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.Tomo
Gifts in chat (opens the original)
Read excerpt
<img alt="" class="sizing-normal" height="316" src="https://substackcdn.com/image/fetch/$s_!zzVV!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4463d4a9-3f41-4b87-b60a-19ab8361bea6_474x316.png" w
12 Rules That Keep You in the Game (opens the original)
Read excerpt
Investing is not about being the smartest person in the room. It is about staying in the game long enough to let good decisions compound. These are the rules I live by, and every one of them has saved me money. If you are new here, pin this.This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.<input class="button
The WTF Overnight Limit (opens the original)
Read excerpt
The dumbest-looking thing I do on purpose, and why I keep doing it.When I actually want to buy or sell, I don’t just sit a limit at a “reasonable” price during regular hours. I park a wild overnight limit. A shot-in-the-dark number. The kind of print that makes you say wait, that can’t be right when you wake up.Most of the time it does nothing. That’s the point. It’s a lottery ticket with a defined price, sitting in a thin book while everyone else is asleep.Two recent examples: one buy, one sell
Monthly Picks & Shovel Deep Dive Oct 2026 (opens the original)
Read excerpt
COR (Cencora, Inc.) : the toll booth on every prescription in AmericaNo binary catalyst on the calendar. This is a compounder entry, not an event trade. Next earnings November 4, 2026.Price $306.92, off the 52 week high of $377.54 set earlier this year but still well above the $244.82 low, a wide enough range that it tells you this is a name the market keeps repricing on sentiment about specialty distribution and regulatory risk rather than on any single data point.Cencora was founded by Emil P.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.